nope, you got it... Inmed is well on its way to securing their process through patent protection, they've been steadily building out their team over the last 18 months to prep for scaling, and have their own compounds in the pipeline as well.
BUT - We're still seeing a lot of the market focusing on 1st generation cannabis plays; growers, equipment vendors, and a few 'competitors' in biotech who rely on farmed resource material. Obviously GW is the big kahuna in that regard, having made a name for itself in the mainstream. But much of the weed investing world is still on the fringes of general public awareness.
Inmed is a gen 2 cannabis company, however. They had metalevel vision to see the future of the market evolving, developing in a certain direction, and very early on anticipated the need that direction would create. I firmly believe that their tech has the potential to be a weed gen 1 company killer. Being able to produce stable, quality controlled compounds, with a lower geographical and environmental impact compared to farms is potentially HUGE (see insulin)
Historically (pre 2017), Inmed seems to have focused purely on meeting internal milestones, with little concern about building public awareness. Over the last year, though, we've seen the impact of the addition of a PR/News agent to push Inmed's succcesses to the fore. This can be recognized in the amount of new money flowing into the ticker, and the volume steadily creeping up over the year.
BUT - we're still very much on the fringes here; OTCBB is unappealing/invisible to a large majority of retail investors, and institutional investors typically can't/don't get involved until market cap is well above where we stand now.
So, we're not 'there' yet; Inmed has done exceptionally well at putting together a string of news hits without an "oh shit!" moment (remember when GW announced they couldn't validate the accuracy of their books after their uplisting? I remember that 50+% haircut). But there's still a long road to go before we're in ten-bagger or more territory here...
I have strong confidence that the team will continue to steadily build value for shareholders. Engaging an external auditor is a recent positive signal, and there are plenty of announcements that could make 2018 an exciting year. Big shifts in value will come through events like signing big partnerships, more marquee hires, ramping up production, moving to a more visible/reputable exchange, etc.
Personally I've held Inmed for the last 3 years or so, averaging down and accumulating where I could (never enough though!). I'm not in it to make a quick buck, nor do I trade the short term swings in value... I'm just sitting back, slowly watching my money tsunami get ready to come ashore :)
